Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B Ejlertsen, J Aldridge, K V Nielsen, M M Regan, K L Henriksen, Anne Lykkesfeldt, S Müller, R D Gelber, K N Price, B B Rasmussen, G Viale, H Mouridsen, for the Danish Breast Cancer Cooperative Group, the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group

17 Citationer (Scopus)

Abstract

BACKGROUND: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis. PATIENTS AND METHODS: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥1% after central review. RESULTS: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind23
Udgave nummer5
Sider (fra-til)1138-1144
ISSN0923-7534
DOI
StatusUdgivet - 10 okt. 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater